Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Ghia

Showing results (1-10 of 373) with videos related to

Pageof 38
Sort By:
Frontiers in Immunology|November 10, 2018
From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia DevelopmentPaolo Ghia
The Lancet. Haematology|March 8, 2016
A new life for rituximab?Paolo Ghia
Clinical Advances in Hematology & Oncology : H&O|January 21, 2022
Recent data for acalabrutinib in chronic lymphocytic leukemiaPaolo Ghia
Haematologica|August 4, 2011
Another piece of the puzzle: is there a "nodal" monoclonal B-cell lymphocytosis?Paolo Ghia
The Lancet. Haematology|December 22, 2015
Targeting Hedgehog in haematological malignanciesPaolo Ghia
The Lancet. Oncology|September 18, 2016
Ibrutinib holds promise for patients with 17p deletion CLLPaolo Ghia
Hematology. American Society of Hematology. Education Program|December 13, 2012
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?Paolo Ghia
The Lancet. Oncology|August 25, 2014
Ibrutinib: better combined with other drugs?Paolo Ghia
Hemasphere|January 6, 2021
EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic LeukemiaBarbara Eichhorst, Paolo Ghia
Blood|June 11, 2026
Minimal residual disease in CLL: when does it really matter?Antonio Cuneo, Paolo Ghia
Pageof 38

Showing results (1-10 of 373) with videos related to

Sort By:
Pageof 38
Frontiers in Immunology|November 10, 2018
From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia DevelopmentPaolo Ghia
The Lancet. Haematology|March 8, 2016
A new life for rituximab?Paolo Ghia
Clinical Advances in Hematology & Oncology : H&O|January 21, 2022
Recent data for acalabrutinib in chronic lymphocytic leukemiaPaolo Ghia
Haematologica|August 4, 2011
Another piece of the puzzle: is there a "nodal" monoclonal B-cell lymphocytosis?Paolo Ghia
The Lancet. Haematology|December 22, 2015
Targeting Hedgehog in haematological malignanciesPaolo Ghia
The Lancet. Oncology|September 18, 2016
Ibrutinib holds promise for patients with 17p deletion CLLPaolo Ghia
Hematology. American Society of Hematology. Education Program|December 13, 2012
A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?Paolo Ghia
The Lancet. Oncology|August 25, 2014
Ibrutinib: better combined with other drugs?Paolo Ghia
Hemasphere|January 6, 2021
EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic LeukemiaBarbara Eichhorst, Paolo Ghia
Blood|June 11, 2026
Minimal residual disease in CLL: when does it really matter?Antonio Cuneo, Paolo Ghia
Pageof 38